Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis.
| Title: | Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis. |
|---|---|
| Authors: | Amani, Bahman1 (AUTHOR), Amani, Behnam1 (AUTHOR) b_amani@alumnus.tums.ac.ir |
| Source: | Immunity, Inflammation & Disease. Apr2024, Vol. 12 Issue 4, p1-11. 11p. |
| Subject Terms: | *MOLNUPIRAVIR, *CORONAVIRUS disease treatment, *COVID-19, *INTENSIVE care units |
| Abstract: | Background and Aim: This systematic review and meta‐analysis aimed to compare the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with coronavirus disease 2019 (COVID‐19). Methods: Cochrane Library, Web of Science, PubMed, medRxiv, and Google Scholar were systematically searched to identify relevant evidence up to December 2023. The risk of bias was assessed using the risk of bias in nonrandomized studies of interventions tool. Data were analyzed using Comprehensive Meta‐Analysis (CMA). Results: Our search identified and included 13 studies involving 16166 patients. The meta‐analysis revealed a significant difference between the molnupiravir and sotrovimab groups in terms of the mortality rate (odds ratio [OR] = 2.07, 95% confidence interval [CI]: 1.16, 3.70). However, no significant difference was observed between the two groups in terms of hospitalization rate (OR = 0.71, 95% CI: 0.47, 1.06), death or hospitalization rate (OR = 1.51, 95% CI: 0.81, 2.83), and intensive care unit admission (OR = 0.59, 95% CI: 0.07, 4.84). In terms of safety, molnupiravir was associated with a higher incidence of adverse events (OR = 1.67, 95% CI: 1.21, 2.30). Conclusion: The current findings indicate that sotrovimab may be more effective than molnupiravir in reducing the mortality rate in COVID‐19 patients. However, no statistical difference was observed between the two treatments for other effectiveness outcomes. The certainty of evidence for these findings was rated as low or moderate. Further research is required to provide a better comparison of these interventions in treating COVID‐19 patients. [ABSTRACT FROM AUTHOR] |
| Copyright of Immunity, Inflammation & Disease is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Academic Search Complete |
| Full text is not displayed to guests. | Login for full access. |
| FullText | Links: – Type: pdflink Text: Availability: 1 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=20504527&ISBN=&volume=12&issue=4&date=20240401&spage=1&pages=1-11&title=Immunity, Inflammation & Disease&atitle=Comparison%20of%20effectiveness%20and%20safety%20of%20molnupiravir%20versus%20sotrovimab%20for%20COVID%E2%80%9019%3A%20A%20systematic%20review%20and%20meta%E2%80%90analysis.&aulast=Amani%2C%20Bahman&id=DOI:10.1002/iid3.1262 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: a9h DbLabel: Academic Search Complete An: 176897817 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Amani%2C+Bahman%22">Amani, Bahman</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Amani%2C+Behnam%22">Amani, Behnam</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> b_amani@alumnus.tums.ac.ir</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Immunity%2C+Inflammation+%26+Disease%22">Immunity, Inflammation & Disease</searchLink>. Apr2024, Vol. 12 Issue 4, p1-11. 11p. – Name: Subject Label: Subject Terms Group: Su Data: *<searchLink fieldCode="DE" term="%22MOLNUPIRAVIR%22">MOLNUPIRAVIR</searchLink><br />*<searchLink fieldCode="DE" term="%22CORONAVIRUS+disease+treatment%22">CORONAVIRUS disease treatment</searchLink><br />*<searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br />*<searchLink fieldCode="DE" term="%22INTENSIVE+care+units%22">INTENSIVE care units</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background and Aim: This systematic review and meta‐analysis aimed to compare the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with coronavirus disease 2019 (COVID‐19). Methods: Cochrane Library, Web of Science, PubMed, medRxiv, and Google Scholar were systematically searched to identify relevant evidence up to December 2023. The risk of bias was assessed using the risk of bias in nonrandomized studies of interventions tool. Data were analyzed using Comprehensive Meta‐Analysis (CMA). Results: Our search identified and included 13 studies involving 16166 patients. The meta‐analysis revealed a significant difference between the molnupiravir and sotrovimab groups in terms of the mortality rate (odds ratio [OR] = 2.07, 95% confidence interval [CI]: 1.16, 3.70). However, no significant difference was observed between the two groups in terms of hospitalization rate (OR = 0.71, 95% CI: 0.47, 1.06), death or hospitalization rate (OR = 1.51, 95% CI: 0.81, 2.83), and intensive care unit admission (OR = 0.59, 95% CI: 0.07, 4.84). In terms of safety, molnupiravir was associated with a higher incidence of adverse events (OR = 1.67, 95% CI: 1.21, 2.30). Conclusion: The current findings indicate that sotrovimab may be more effective than molnupiravir in reducing the mortality rate in COVID‐19 patients. However, no statistical difference was observed between the two treatments for other effectiveness outcomes. The certainty of evidence for these findings was rated as low or moderate. Further research is required to provide a better comparison of these interventions in treating COVID‐19 patients. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Immunity, Inflammation & Disease is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=176897817 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/iid3.1262 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1 Subjects: – SubjectFull: MOLNUPIRAVIR Type: general – SubjectFull: CORONAVIRUS disease treatment Type: general – SubjectFull: COVID-19 Type: general – SubjectFull: INTENSIVE care units Type: general Titles: – TitleFull: Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Amani, Bahman – PersonEntity: Name: NameFull: Amani, Behnam IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: Apr2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 20504527 Numbering: – Type: volume Value: 12 – Type: issue Value: 4 Titles: – TitleFull: Immunity, Inflammation & Disease Type: main |
| ResultId | 1 |